UBS Chief European Equity Strategist and Head of Derivates Gerry Fowler said he sees value in US cyclicals and pharmaceuticals as markets digest a tech selloff, according to Bloomberg.
Fowler told Bloomberg Television he expects volatility to persist, saying it is “an artifice of market structure” that he does not think is going away.
UBS' Fowler Sees Value in US Cyclicals, Pharmaceuticals
2026-06-24 08:00:33
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
